Skip to Content
 

News: Research

VISE team seeks to develop new robot to ease prostatectomies

Thursday, April 25th, 2019

The Vanderbilt Institute for Surgery and Engineering (VISE) team of Robert Webster III, PhD, and Duke Herrell, MD, have received a $2.2 million grant from the National Institutes of Health to develop a new surgical robot for endoscopic transurethral prostatectomy.

Study reframes approach to targeted therapy resistance

Thursday, April 25th, 2019

A recent study provides clinicians genomic guidance for surveillance of targeted therapy resistance in patients with EGFR-mutant non-small cell lung cancer — and more importantly — another drug option when resistance occurs.

Discovery aids search for cancer biomarkers

Thursday, April 25th, 2019

A report by researchers at Vanderbilt University Medical Center has shattered conventional wisdom about how cells, including cancer cells, shed DNA into the bloodstream: they don’t do it by packaging the genetic material in tiny vesicles called exosomes.

Cancer Center’s annual scientific retreat set for May 1

Thursday, April 25th, 2019

The 20th Annual Scientific Retreat will be held Wednesday, May 1, 8:30 a.m. to 3 p.m., at the Vanderbilt University Student Life Center. Registration is free, but attendees should register by April 26. The topic of the retreat is “Signal Transduction in Cancer Initiation, Progression and Treatment.”

Like racecars and geese, cancer cells draft their way to new tumor sites

Friday, April 5th, 2019

Finding gives boost to fighting cancer through cell metabolism

Cancer’s SOS

Thursday, April 4th, 2019

Uncontrolled activation of RAS causes approximately a third of all tumors and helps cancerous cells evade anti-cancer drugs. Vanderbilt researchers have identified small molecules that target this pathway and further defined how these small molecule compounds work.

Cancer prevention drug also disables H. pylori bacterium

Thursday, April 4th, 2019

Vanderbilt investigators report that a medicine currently being tested as a chemoprevention agent for multiple types of cancer can also act directly reduce the virulence of Helicobacter pylori, the primary cause of gastric cancer.

Correctly copying DNA

Friday, March 15th, 2019

A precise understanding of how the enzyme topoisomerase II cuts DNA could lead to better anti-cancer therapies.

Cancer Center Ambassadors surpass $1 million in grants

Friday, March 15th, 2019

Vanderbilt-Ingram Cancer Center Ambassadors surpassed the $1 million mark with the awarding of the group’s latest research grants.

Achilles’ heel for kidney cancer

Monday, March 4th, 2019

A recent study found that renal cell carcinoma cells with mutations in an enzyme-encoding gene, SETD2, were sensitive to a drug that inhibits the enzyme PI3K-beta.

Next Page »« Previous Page